Mga Batayang Estadistika
| LEI | 549300V5IF65437JKG30 |
| CIK | 1326732 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Xencor, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 6, 2025 |
Xencor Reports Second Quarter 2025 Financial Results Exhibit 99.1 Xencor Reports Second Quarter 2025 Financial Results PASADENA, Calif.-August 6, 2025- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2025 and provided recent business and clinical program updates. "Xencor i |
|
| August 6, 2025 |
Xencor, Inc. Amended and Restated 2023 Equity Incentive Plan. Exhibit 10.1 Xencor, Inc. Amended and Restated 2023 Equity Incentive Plan Adopted by the Board of Directors: April 18, 2025 Approved by the Stockholders: June 12, 2025 1.General. (a)Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the C |
|
| July 31, 2025 |
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors Exhibit 99.1 Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors PASADENA, Calif.-July 3131, 2025- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a pioneering biochemist and |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 7, 2025 |
Exhibit 99.1 Xencor Reports First Quarter 2025 Financial Results - Recent interim Phase 1 study results for XmAb942 (Xtend™ anti-TL1A) support a 12-week maintenance dosing interval in XENITH-UC, a Phase 2b study in participants with ulcerative colitis, to begin in the second half of 2025 - - Chief development officer and former independent director, Nancy Valente, M.D., to transition to senior adv |
|
| May 7, 2025 |
Exhibit 10.1 ***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.*** April 19, 2024 John Kuch [...***...] [...***...] Re: Separation Agreement Dear John, This letter sets forth the substance o |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 30, 2025 |
xncr-20250429xexx991 ® Interim Results from First-in-Human Study of XmAb942 & TL1A Pipeline Update April 29, 2025 2 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| April 30, 2025 |
Exhibit 99.2 Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease - XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 - - Single and multiple doses of XmAb942 are well tolerate |
|
| April 30, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 13, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (C |
|
| March 13, 2025 |
Letter from RSM US LLP, dated March 12, 2025. 44 Montgomery St Suite 3900 San Francisco, CA 94104 T +1 415 848 5300 F +1 415 848 5353 www.rsmus.com March 12, 2025 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read Xencor, Inc.’s statements included under Item 4.01(a) of its Form 8-K filed on March 5, 2025, and we agree with such statements concerning our firm. |
|
| March 13, 2025 |
Xencor Appoints Todd Simpson to Board of Directors Exhibit 99.1 Xencor Appoints Todd Simpson to Board of Directors PASADENA, Calif.- Mar. 13, 2025- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial off |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 5, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 27, 2025 |
Exhibit 10.6 Xencor, Inc. 2023 Equity Incentive Plan Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Xencor, Inc. (the “Company”) has granted you an option under its 2023 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Gra |
|
| February 27, 2025 |
CORP-LEG-003 Rev. 6 Title: Insider Trading Policy POLICY: It is the policy of Xencor, Inc. (“Company”) that directors, officers and other employees and consultants (and any persons to whom they disclose such information) shall not Trade (defined below) securities of the Company or another publicly-traded company with which the Company has business dealings (a “Third Party”) when in the possession |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 27, 2025 |
List of Subsidiaries of Xencor, Inc. Exhibit 21.1 XENCOR, INC. The following is the subsidiary of the Company as of December 31, 2024: SUBSIDIARY (Name under which subsidiary does business) STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Gale Therapeutics Inc. Delaware |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36182 Xencor, Inc. |
|
| February 27, 2025 |
Exhibit 10.30 ***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.*** Xencor, Inc. 111 West Lemon Avenue Monrovia, CA 91016 Attn: Bassil Dahiyat, CEO Fax: +1 626 305 0350 Copy: Morisson & fore |
|
| February 27, 2025 |
Form of Restricted Stock Unit Agreement Exhibit 10.7 Xencor, Inc. 2023 Equity Incentive Plan Restricted Stock Unit Award Agreement Pursuant to the Restricted Stock Unit Grant Notice (the “Grant Notice”) and this Restricted Stock Unit Award Agreement (the “Agreement”), Xencor, Inc. (the “Company”) has awarded you (“Participant”) an RSU Award (the “Award”) pursuant to Section 5 of the Company’s 2023 Equity Incentive Plan (the “Plan”) for |
|
| February 27, 2025 |
Exhibit 10.29 ***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.*** CONFIDENTIAL Execution Copy COLLABORATION AND LICENSE AGREEMENT This COLLABORATION AND LICENSE AGREEMENT (this “Agreement” |
|
| February 27, 2025 |
Exhibit 4.3 DESCRIPTION OF SECURITIES The following is a summary description of the material terms of capital stock of Xencor, Inc. (we, our or us), as well as other material terms of our amended and restated certificate of incorporation (Certificate of Incorporation) and our second amended and restated bylaws (Bylaws) and certain provisions of the DGCL. This summary does not purport to be complet |
|
| February 27, 2025 |
Research and License Agreement effective September 15, 2015 between the Company and Amgen Inc EXHIBIT 10.34 ***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit.*** CONFIDENTIAL EXECUTION VERSION RESEARCH AND LICENSE AGREEMENT This Research and License Agreement (the “Agreement”) is ent |
|
| February 27, 2025 |
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Xencor Reports Fourth Quarter and Full Year 2024 Financial Results PASADENA, Calif.-(BUSINESS WIRE)-Feb. 27, 2025- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided clinical |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. |
|
| February 24, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis |
|
| February 24, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C |
|
| February 24, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2025 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 13, 2025 |
om RSM US LLP, dated February 13, 2025. 44 Montgomery St Suite 3900 San Francisco, CA 94104 T +1 415 848 5300 F +1 415 848 5353 www.rsmus.com February 13, 2025 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read Xencor, Inc.’s statements included under Item 4.02(b) of its Form 8-K filed on February 13, 2025, and we agree with such statements regarding communications from our firm. |
|
| January 13, 2025 |
® Proteins by Design® XmAb® Antibody Therapeutics Corporate Overview January 2025 2 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 14, 2024 |
XNCR / Xencor, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Xencor, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 98401F105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| November 12, 2024 |
XNCR / Xencor, Inc. / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 xncra16111124.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 16)* Xencor, Inc. (Name of Issuer) COM (Title of Class of Securities) 98401F105 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des |
|
| November 6, 2024 |
Xencor Reports Third Quarter 2024 Financial Results Exhibit 99.1 Xencor Reports Third Quarter 2024 Financial Results PASADENA, Calif- Nov. 6, 2024- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage prog |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 21, 2024 |
ZBIO / Zenas BioPharma, Inc. / Xencor Inc - SC 13G Passive Investment SC 13G 1 zenasbiopharmainc-xencorsc.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zenas BioPharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 98937L105 (CUSIP Number) September 16, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| October 18, 2024 |
XNCR / Xencor, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 XencorInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* XENCOR INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 98401F105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 4, 2024 |
Xencor Announces Upcoming Change to Board of Directors Exhibit 99.1 Xencor Announces Upcoming Change to Board of Directors PASADENA, Calif.- Oct. 4, 2024- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that Dagmar Rosa-Bjorkeson has informed the Company that she will not stand for reelection to the Company’s Board of Direct |
|
| October 2, 2024 |
INMB / INmune Bio, Inc. / Xencor Inc - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 12, 2024 |
Form of Pre-Funded Warrant to Purchase Common Stock. Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: September [ ], 2024 XENCOR, INC. Xencor, Inc., a [Delaware] corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [Investor Name] or its registered assigns (the |
|
| September 12, 2024 |
Exhibit 1.1 XENCOR, INC. (a Delaware corporation) 6,635,112 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,088,888 Shares of Common Stock UNDERWRITING AGREEMENT September 10, 2024 Leerink Partners LLC Raymond James & Associates, Inc. RBC Capital Markets, LLC as Representatives of the several Underwriters c/o Leerink Partners LLC 255 California St., 5th Floor San Francisco, CA 94111 |
|
| September 12, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-270030 PROSPECTUS SUPPLEMENT (To Prospectus dated February 27, 2023) 6,635,112 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,088,888 Shares of Common Stock We are offering 6,635,112 shares of our common stock, par value $0.01 per share, and, in lieu of offering shares of our common stock to certain investors who so choose, pre- |
|
| September 12, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 12, 2024 |
Xencor Announces Pricing of $175 Million Public Offering of Common Stock Exhibit 99.2 Xencor Announces Pricing of $175 Million Public Offering of Common Stock PASADENA, Calif. – Sept. 11, 2024 – Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the pricing of its underwritten public offering of (i) 6,635,112 shares of its common stoc |
|
| September 12, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 10, 2024 Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 12, 2024 |
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares PASADENA, Calif. |
|
| September 12, 2024 |
Xencor Announces Proposed Public Offering of Common Stock Exhibit 99.1 Xencor Announces Proposed Public Offering of Common Stock PASADENA, Calif. – Sept. 10, 2024 – Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of commo |
|
| September 12, 2024 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 Xencor Inc Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| September 10, 2024 |
Subject to Completion, Dated SEPTEMBER 10, 2024 Filed pursuant to Rule 424(b)(5) Registration No. 333-270030 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell these securities, a |
|
| September 9, 2024 |
® Xencor R&D Strategy Call September 9, 2024 2 Today’s Agenda Overview Rationale for bispecific antibodies in autoimmune & inflammatory diseases New pipeline programs: B-cell depleting T-cell engagers Plamotamab (CD20 x CD3) XmAb657 (CD19 x CD3) New pipeline programs: TL1A portfolio XmAb942 (Xtend TL1A) XmAb TL1A x IL-23 Potential first-in-class T-Cell engagers in solid tumor oncology XmAb819 (ENPP3 x CD3) XmAb808 (B7-H3 x CD28) 3 Forward Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| September 9, 2024 |
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs - Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 - - XmAb® T-cell engagers plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3) to be evaluated in autoimmune diseases, with respective Phase 1b/2a and Phase 1 studies to initiate in 2025 - - Ongoing Phase 1 dose escalation of XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma shows initial encouraging clinical activity including RECIST responses - - Management hosting webcast and conference call at 8:00 a. |
|
| September 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 5, 2024 |
Consulting Agreement by and between the Company and John J. Kuch, dated April 19, 2024. Exhibit 10.1 XENCOR, INC. CONSULTING AGREEMENT Effective Date: April 19, 2024 This Consulting Agreement (the “Agreement”) is made as of the Effective Date set forth above by and between Xencor, Inc. (“Client”) and the consultant named on the signature page hereto (“Consultant”). WHEREAS, Client and Consultant entered into and agreed to a consulting arrangement on April [x], 2024 for Consultant to |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 5, 2024 |
Xencor Reports Second Quarter 2024 Financial Results Exhibit 99.1 Xencor Reports Second Quarter 2024 Financial Results PASADENA, Calif.-Aug. 5, 2024- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the second quarter ended June 30, 2024 and provided a review of recent business updates and internal clini |
|
| August 5, 2024 |
by and between the Company and Nancy Valente Executive Employment Letter Addendum #2 Whereas, Nancy Valente (“Executive”) is employed by Xencor, Inc. |
|
| June 14, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 13, 2024 |
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager Exhibit 99.1 Xencor Regains CD20 x CD3 Bispecific T-Cell Engager PASADENA, Calif.-June 13, 2024- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase |
|
| June 13, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 9, 2024 |
Fourth AMENDMENT TO THE LICENSE AGREEMENT BY AND BETWEEN XENCOR, INC. AND MorphoSys AG This fourth amendment ("Amendment") to the COLLABORATION AND LICENSE AGREEMENT dated June 27, 2010, as amended on March 23, 2012, on January 8, 2020 and on July 13, 2020 (collectively, the “Agreement”), by and between XENCOR, INC., a Delaware corporation with its principal offices at 465 N. Halstead Street, Suit |
|
| May 9, 2024 |
by and between the Company and Exhibit 10.3 April 7, 2023 Dr. Nancy Valente Dear Dr. Valente, Congratulations! I am pleased to confirm our contingent offer of a position as Executive Vice President & Chief Development Officer, reporting to Bassil Dahiyat, CEO and starting on May 1, 2023 or another mutually agreeable date (“Start Date”). This position’s primary location is Pasadena, CA. The specifics of this offer are as follows |
|
| May 9, 2024 |
Xencor Reports First Quarter 2024 Financial Results Exhibit 99.1 Xencor Reports First Quarter 2024 Financial Results PASADENA, Calif.-May 9, 2024- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights. “We |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 9, 2024 |
Employment Agreement dated March 11, 2024 by and between the Company and Bart Jan Cornelissen. Exhibit 10.2 March 11, 2024 Bart Cornelissen 7614 Overlake Drive W Medina, WA 98039 Dear Bart Cornelissen, Congratulations! I am pleased to confirm our contingent offer of a position as Senior Vice President & Chief Financial Officer, reporting to Bassil Dahiyat, CEO and starting on April 9, 2024 or another mutually agreeable date (the “Start Date”). This position’s location is Remote in the state |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 9, 2024 |
THIRD AMENDMENT TO LEASE (465 North Halstead) THIS THIRD AMENDMENT TO LEASE (“Third Amendment”) is made and entered into as of the 26th day of January, 2024, by and between AG-LC 465 NORTH HALSTEAD OWNER, L. |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 9, 2024 |
Xencor Appoints Bart Cornelissen as Chief Financial Officer Exhibit 99.1 Xencor Appoints Bart Cornelissen as Chief Financial Officer PASADENA, Calif. - April 9, 2024 - Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more t |
|
| March 6, 2024 |
® Proteins by Design® XmAb® Antibody Therapeutics Corporate Overview March 2024 2 Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, may constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| March 6, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 29, 2024 |
Exhibit 97 XENCOR, INC. COMPENSATION RECOVERY POLICY Adopted as of September 15, 2023 Xencor, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1.Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and former Executive Officers o |
|
| February 29, 2024 |
Exhibit 10.47 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE XENCOR, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO XENCOR, INC. IF PUBLICLY DISCLOSED. CONFIDENTIAL EXECUTION COPY AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN, on the one hand, XENCOR, INC., AND |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36182 Xencor, Inc. |
|
| February 27, 2024 |
Exhibit 99.1 Xencor Reports Fourth Quarter and Full Year 2023 Financial Results - Clinical development focus on high-potential XmAb® T cell engagers and selective dual checkpoint inhibitor, vudalimab - - Vudalimab (PD-1 x CTLA-4) monotherapy generally well tolerated with encouraging clinical benefit for patients with high-risk mCRPC who have advanced beyond standard of care therapy - - Management |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 14, 2024 |
XNCR / Xencor, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Xencor, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 98401F105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 13, 2024 |
XNCR / Xencor, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02311-xencorinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Xencor Inc Title of Class of Securities: Common Stock CUSIP Number: 98401F105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs |
|
| February 12, 2024 |
XNCR / Xencor, Inc. / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 xncra1521224.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 15)* Xencor, Inc. (Name of Issuer) COM (Title of Class of Securities) 98401F105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| November 15, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 8, 2023 |
Exhibit 10.1 Executive Employment Agreement Addendum Whereas, Employee is employed by Xencor as its Senior Vice President, General Counsel & Corporate Secretary and Employee is subject to an Employment Letter, dated August 5, 2019 a copy of which is attached as Attachment 1 (“Employment Letter”); Whereas, under the Employment Letter, Employee is entitled to certain severance benefits in connection |
|
| November 8, 2023 |
Exhibit 10.2 Executive Employment Agreement Addendum Whereas, Employee is employed by Xencor as its Executive Vice President & Chief Development Officer and Employee is subject to an Employment Letter, dated April 7, 2023 a copy of which is attached as Attachment 1 (“Employment Letter”); Whereas, under the Employment Letter, Employee is entitled to certain severance benefits in connection with a T |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 7, 2023 |
EXECUTION VERSION CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ROYALTY PURCHASE AGREEMENT XENCOR, INC. |
|
| November 7, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 7, 2023 |
Exhibit 99.1 Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million PASADENA, Calif. – November 7, 2023 - Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial interests |
|
| November 7, 2023 |
EXECUTION VERSION CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ROYALTY PURCHASE AGREEMENT (MONJUVI®/MINJUVI®) XENCOR, INC. |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 7, 2023 |
Exhibit 99.1 Xencor Reports Third Quarter 2023 Financial Results - Royalty Transaction Generates $215 Million Upfront - - Management to Host Conference Call at 4:30 p.m. ET Today - PASADENA, Calif.-Nov. 7, 2023- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, tod |
|
| October 26, 2023 |
Xencor Announces Planned Retirement of Chief Financial Officer John Kuch Exhibit 99.1 Xencor Announces Planned Retirement of Chief Financial Officer John Kuch PASADENA, Calif. - Oct. 26, 2023 - Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that John J. Kuch, senior vice president and chief financial officer, plans to retire in March 202 |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 19, 2023 |
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors Exhibit 99.1 Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors PASADENA, Calif.-September 19, 2023- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J. Klencke, M.D., to its board of directors. Dr. Klencke has more than 2 |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 3, 2023 |
Exhibit 10.1 [***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This First Amendment to the Collaboration and License Agreement (th |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 3, 2023 |
Exhibit 99.1 Xencor Reports Second Quarter 2023 Financial Results - Management to Host Conference Call at 4:30 p.m. ET Today - PASADENA, Calif.-August 3, 2023- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the second quarter |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 15, 2023 As filed with the Securities and Exchange Commission on June 15, 2023 Registration Nos. |
|
| June 16, 2023 |
EX-FILING FEES 2 xncr-20230615xsx8xexh107fi.htm EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Regis |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 15, 2023 As filed with the Securities and Exchange Commission on June 15, 2023 Registration No. |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 15, 2023 As filed with the Securities and Exchange Commission on June 15, 2023 Registration Nos. |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 15, 2023 As filed with the Securities and Exchange Commission on June 15, 2023 Registration Nos. |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 15, 2023 As filed with the Securities and Exchange Commission on June 15, 2023 Registration Nos. |
|
| June 15, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 8, 2023 |
Exhibit 99.1 Xencor Reports First Quarter 2023 Financial Results - Management to Host Conference Call at 4:30 p.m. ET Today - PASADENA, Calif.-May 8, 2023- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ende |
|
| May 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Pro |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 26, 2023 |
xncr2023equityincentivep LEGALUSW # 115236691.3 1 XENCOR, INC. 2023 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 20, 2023 APPROVED BY THE STOCKHOLDERS: [], 2023 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the suc |
|
| April 26, 2023 |
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer Exhibit 99.1 Xencor Appoints Nancy Valente, M.D., as Chief Development Officer PASADENA, Calif. - April 26, 2023 - Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer. Dr |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 27, 2023 |
Exhibit 4.4 XENCOR, INC. SENIOR DEBT SECURITIES INDENTURE Dated as of Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 7 Section 2.03 Denominations: Provisions |
|
| February 27, 2023 |
Table of Contents` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36182 Xencor, Inc. |
|
| February 27, 2023 |
SECOND AMENDED AND RESTATED BYLAWS OF XENCOR, INC. (A DELAWARE CORPORATION) Table Of Contents Page ARTICLE I Offices 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II Corporate Seal 1 Section 3. Corporate Seal 1 ARTICLE III Stockholders’ Meetings 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 4 Section 7. Notice of Meetings 5 Section |
|
| February 27, 2023 |
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| February 27, 2023 |
SIXTH AMENDMENT TO LEASE This SIXTH AMENDMENT TO LEASE (this “Amendment”) is made and effective as of October 18, 2022 (the “Effective Date”) by and between 111 LEMON INVESTORS LLC, a California limited liability company successor-in-interest to BF Monrovia, LLC, a California limited liability company (“Landlord”) and XENCOR, INC. |
|
| February 27, 2023 |
As filed with the Securities and Exchange Commission on February 27, 2023 As filed with the Securities and Exchange Commission on February 27, 2023 Registration No. |
|
| February 27, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carr |
|
| February 27, 2023 |
Exhibit 1.2 XENCOR, INC. Shares of Common Stock ($0.01 par value per share) SALES AGREEMENT February 27, 2023 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Xencor, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows: 1. Issuance and Sale of Shares. The C |
|
| February 27, 2023 |
Approved September 8, 2022 Xencor, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is a member as of July 1, 2021 (the “Effective Date”) and who is not also serving as an employee of Xencor, Inc. (“Xencor”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this |
|
| February 27, 2023 |
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| February 27, 2023 |
Form of Subordinated Indenture. Exhibit 4.5 XENCOR, INC. SUBORDINATED DEBT SECURITIES INDENTURE Dated as of Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 7 Section 2.03 Denominations: Prov |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 23, 2023 |
Exhibit 99.1 Xencor Reports Fourth Quarter and Full Year 2022 Financial Results - Management to Host Conference Call at 4:30 p.m. ET Today - MONROVIA, Calif.-Feb. 23, 2023- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter |
|
| February 15, 2023 |
INMB / INmune Bio Inc. Common stock / Xencor Inc - SC 13G Passive Investment SC 13G 1 inmunebioinc-xencorsc13g20.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* INmune Bio, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45782T105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 13, 2023 |
XNCR / Xencor Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Xencor, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 98401F105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 9, 2023 |
XNCR / Xencor Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 xncra1420923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14)* Xencor, Inc. (Name of Issuer) COM (Title of Class of Securities) 98401F105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 9, 2023 |
XNCR / Xencor Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02279-xencorinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Xencor Inc. Title of Class of Securities: Common Stock CUSIP Number: 98401F105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pur |
|
| December 8, 2022 |
XNCR / Xencor Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13)* Xencor, Inc. (Name of Issuer) COM (Title of Class of Securities) 98401F105 (CUSIP Number) November 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 XENCOR, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-36182 ? 20-1622502 ? (State or other jurisdiction of incorporation) (Commis |
|
| November 7, 2022 |
Exhibit 99.1 ? Xencor Reports Third Quarter 2022 Financial Results - XmAb564, engineered IL-2 cytokine, is well-tolerated and generates a durable, dose-dependent and selective expansion of Tregs in single-dose, healthy volunteer study - - Management to host conference call at 4:30 p.m. ET Today - MONROVIA, Calif.- Nov. 7, 2022- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company |
|
| November 7, 2022 |
Exhibit 99.2 ? Xencor Q3 2022 Financial Results XmAb?564 Data Presentation November 7, 2022 2 Speakers Bassil Dahiyat, Ph.D. President Chief Executive Officer Director John Kuch Senior Vice President & Chief Financial Officer John Desjarlais, Ph.D. Senior Vice President Chief Scientific Officer Allen Yang, M.D., Ph.D. Senior Vice President Chief Medical Officer Ralph Zitnik, M.D. Executive Medical |
|
| November 7, 2022 |
Exhibit 10.1 SECOND AMENDMENT TO LEASE (465 North Halstead) THIS SECOND AMENDMENT TO LEASE (?Second Amendment?) is made and entered into as of the 2nd day of August, 2022, by and between AG-LC 465 NORTH HALSTEAD OWNER, L.P., a Delaware limited partnership (?Landlord?) and XENCOR, INC., a Delaware corporation (?Tenant?). R E C I T A L S: A.Landlord and Tenant entered into that certain Lease dated a |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): September 9, 2022 XENCOR, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission |
|
| September 9, 2022 |
Xencor Appoints Nancy Valente, M.D., to Board of Directors Exhibit 99.1 ? Xencor Appoints Nancy Valente, M.D., to Board of Directors MONROVIA, Calif.-September 9, 2022- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to its board of directors. Dr. Valente has more than 20 years o |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 XENCOR, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-36182 ? 20-1622502 ? (State or other jurisdiction of incorporation) (Commissi |
|
| August 3, 2022 |
As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No. |
|
| August 3, 2022 |
Exhibit 99.1 Xencor Reports Second Quarter 2022 Financial Results - Management to Host Conference Call at 4:30 p.m. ET Today - MONROVIA, Calif.-August 3, 2022- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30 |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 3, 2022 |
? Exhibit 10.1 FIRST AMENDMENT TO OFFICE LEASE This First Amendment to Office Lease (this ?First Amendment?) is made and entered into by and between PRII HIGH BLUFFS, LLC, a Delaware limited liability company and COLLINS CORPORATE CENTER PARTNERS, LLC, a Delaware limited liability company, as tenants in common (collectively, ?Landlord?), and XENCOR, INC., a Delaware corporation (?Tenant?), to be e |
|
| August 3, 2022 |
? Calculation of Filing Fee Tables Form S-8 (Form Type) Xencor, Inc. (Exact Name of Registrant as Specified in its Charter) ? Table 1: Newly Registered Securities ? ? ? ? ? (1) ? ? ? (2)? ? ? ? ? ? (5)? ? Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(5) Eq |
|
| June 28, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 23, 2022 XENCOR, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File |
|
| May 5, 2022 |
Exhibit 99.1 Xencor Reports First Quarter 2022 Financial Results ? - Management to Host Conference Call at 4:30 p.m. ET Today - ? MONROVIA, Calif.-May 5, 2022- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31 |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 XENCOR, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-36182 ? 20-1622502 ? (State or other jurisdiction of incorporation) (Commission |
|
| April 27, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 27, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definiti |
|
| February 24, 2022 |
Xencor, Inc. Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.38 Xencor, Inc. Amended and Restated Non-Employee Director Compensation Policy ? Each member of the Board of Directors (the ?Board?) who is a member as of July 1, 2021 (the ?Effective Date?) and who is not also serving as an employee of Xencor, Inc. (?Xencor?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Amended an |
|
| February 24, 2022 |
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ? Commission file number: 001-36182 Xencor, Inc. |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 XENCOR, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-36182 ? 20-1622502 ? (State or other jurisdiction of incorporation) (Commi |
|
| February 23, 2022 |
Exhibit 99.1 Xencor Reports Fourth Quarter and Full Year 2021 Financial Results ? - Management to Host Conference Call at 4:30 p.m. ET Today - ? MONROVIA, Calif.-Feb. 23, 2021- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quar |
|
| February 14, 2022 |
XNCR / Xencor Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Xencor, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 98401F105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 10, 2022 |
INMB / INmune Bio Inc. Common stock / Xencor Inc - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2022 |
XNCR / Xencor Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Xencor Inc. Title of Class of Securities: Common Stock CUSIP Number: 98401F105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13 |
|
| February 10, 2022 |
XNCR / Xencor Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* Xencor, Inc. (Name of Issuer) COM (Title of Class of Securities) 98401F105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 XENCOR, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-36182 ? 20-1622502 ? (State or other jurisdiction of incorporation) (Commis |
|
| November 8, 2021 |
Exhibit 99.1 Xencor Reports Thirds Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306 ? - Management to Host Conference Call at 4:30 p.m. ET Today - ? MONROVIA, Calif.-Nov. 8, 2021- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cyto |
|
| October 4, 2021 |
Exhibit 99.1 ? ? Xencor Enters Global Collaboration and License Agreement with Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients with B-Cell Malignancies ? - Second agreement with Janssen on bispecific antibodies directed toward the CD28 co-stimulatory receptor on T cells - ? - Xencor to receive $100 million upfront payment and $25 million e |
|
| October 4, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): October 1, 2021 XENCOR, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 XENCOR, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-36182 ? 20-1622502 ? (State or other jurisdiction of incorporation) (Commissi |
|
| August 4, 2021 |
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| August 4, 2021 |
? Exhibit 10.2 ? AGREEMENT OF LEASE (465 North Halstead) THIS AGREEMENT OF LEASE (?Agreement?) is made and entered into as of the 30th day of April, 2021, by and between ANGELO GORDON REAL ESTATE, INC., a Delaware corporation (?AG?) and XENCOR, INC., a Delaware corporation (?Xencor?). R E C I T A L S: A.AG (as buyer) has entered into a purchase and sale agreement (the ?Purchase Agreement?) with No |
|
| August 4, 2021 |
Exhibit 10.3 ? FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE ("Amendment") is made and entered into as of July 13, 2021, by and between AG-LC 465 NORTH HALSTEAD OWNER, L.P., a Delaware limited partnership ("Landlord"), and XENCOR, INC., a Delaware corporation ("Tenant"). r e c i t a l S: A.ANGELO GORDON REAL ESTATE, INC., a Delaware corporation (?Original Landlord?) and Tenant entered int |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 4, 2021 |
Exhibit 99.1 Xencor Reports Second Quarter 2021 Financial Results ? - Management to Host Conference Call at 4:30 p.m. ET Today - ? MONROVIA, Calif.-August 4, 2021- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarte |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 30, 2021 XENCOR, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File |
|
| June 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 24, 2021 XENCOR, INC. (Exact name of registrant as specified in its charter) ? Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File |
|
| May 5, 2021 |
Exhibit 99.1 Xencor Reports First Quarter 2021 Financial Results - Management to Host Conference Call at 4:30 p.m. ET Today - MONROVIA, Calif.-May 5, 2021- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended M |
|
| May 5, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 5, 2021 |
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| April 28, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definiti |
|
| April 28, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 10, 2021 |
Exhibit 10.1 Xencor, Inc. 2013 Equity Incentive Plan Restricted Stock Unit Award Agreement ? Pursuant to the Restricted Stock Unit Grant Notice (the ?Grant Notice?) and this Restricted Stock Unit Award Agreement (the ?Agreement?), Xencor, Inc. (the ?Company?) has awarded you (?Participant?) a Restricted Stock Unit Award (the ?Award?) pursuant to Section 6(b) of the Company?s 2013 Equity Incentive |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2021 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 24, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ? Commission file number: 001-36182 Xencor, Inc. |
|
| February 24, 2021 |
? ? Execution Version CONFIDENTIAL ? Exhibit 10.32 THIRD AMENDMENT TO THE LICENSE AGREEMENT BY AND BETWEEN XENCOR, INC. AND MorphoSys AG This third amendment ("Amendment") to the COLLABORATION AND LICENSE AGREEMENT dated June 27, 2010, as amended on March 23, 2012, and on January 8, 2020 (such second amendment being wrongly named ?first amendment? thereunder shall be regarded and referred to as th |
|
| February 24, 2021 |
? Exhibit 10.33 FIFTH AMENDMENT TO LEASE This FIFTH AMENDMENT TO LEASE (this ?Amendment?) is made and effective as of October 31, 2020 (the ?Effective Date?) by and between 111 LEMON INVESTORS LLC, a California limited liability company successor-in-interest to BF Monrovia, LLC, a California limited liability company (?Landlord?) and XENCOR, INC., a Delaware corporation successor-in-interest to Xe |
|
| February 24, 2021 |
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| February 24, 2021 |
Execution Version [***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| February 24, 2021 |
Execution Version ? Exhibit 10.31 First Amendment to the License Agreement By and Between Xencor, Inc. and MorphoSys AG This first amendment ("Amendment") to the Collaboration and License Agreement dated June 27, 2010 (the ?Agreement?) by and between Xencor, Inc., a Delaware corporation with its principal offices at 111 West Lemon Avenue, Monrovia, CA 91016 (?Xencor?), and MorphoSys AG, a German c |
|
| February 24, 2021 |
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| February 23, 2021 |
Exhibit 99.1 Xencor Reports Fourth Quarter and Full Year 2020 Financial Results ? - Management to Host Conference Call at 4:30 p.m. ET Today - ? MONROVIA, Calif.-Feb. 23, 2021-Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the f |
|
| February 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 XENCOR, INC. (Exact name of registrant as specified in its charter) ? ? ? ? Delaware 001-36182 ? 20-1622502 ? (State or other jurisdiction of incorporation) (Commi |
|
| February 12, 2021 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Xencor Inc. Title of Class of Securities: Common Stock CUSIP Number: 98401F105 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| January 22, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Miragen Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 60463E 202 (CUSIP Number) December 16, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| December 7, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 4, 2020 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 7, 2020 |
Exhibit 99.1 Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer - Research collaboration focused on the discovery of novel bispecific antibodies directed toward the CD28 co-stimulatory receptor and an undisclosed prostate tumor target - - Xencor receives $50 million upfront payment and is eligible to receive potential |
|
| November 30, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 24, 2020 XENCOR, INC. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? ? ? ? Delaware 001-36182 ? 20-1622502 ? (State or other jurisdiction of incorporati |
|
| November 6, 2020 |
Exhibit 10.1 Xencor, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is a member as of July 1, 2020 (the “Effective Date”) and who is not also serving as an employee of Xencor, Inc. (“Xencor”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and R |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 6, 2020 |
Exhibit 10.2 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE (this “Amendment”) is made and effective as of September 30, 2020 (the “Effective Date”) by and between 111 LEMON INVESTORS LLC, a California limited liability company successor-in-interest to BF Monrovia, LLC, a California limited liability company (“Landlord”) and XENCOR, INC., a Delaware corporation successor-in-interest to X |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 5, 2020 |
Exhibit 99.1 Xencor Reports Third Quarter 2020 Financial Results - Management to Host Conference Call at 4:30 p.m. EST Today - MONROVIA, Calif.-Nov. 5, 2020- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, |
|
| October 14, 2020 |
Exhibit 99.1 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors Background XmAb20717 is a humanized bispecific monoclonal antibody that simultaneously targets PD-1 and CTLA-4. We report preliminary data from an ongoing, multicenter, Phase 1 study investigating the safety/tolerabilit |
|
| October 14, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2020 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State of incorporation) (Commission File No.) (IRS Employer Identif |
|
| September 10, 2020 |
XNCR / Xencor, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| September 8, 2020 |
XNCR / Xencor, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| August 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36182 Xencor, Inc. |
|
| August 5, 2020 |
Exhibit 10.1 THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO LEASE (this “Amendment”) is made and effective as of April 30, 2020 (the “Effective Date”) by and between 111 LEMON INVESTORS LLC, a California limited liability company successor-in-interest to BF Monrovia, LLC, a California limited liability company (“Landlord”) and XENCOR, INC., a Delaware corporation successor-in-interest to Xencor, |
|
| August 4, 2020 |
Exhibit 99.1 Xencor Reports Second Quarter 2020 Financial Results - Management to Host Conference Call at 4:30 p.m. ET Today - MONROVIA, Calif.-August 4, 2020- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2 |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State of incorporation) (Commission File No.) (IRS Employer Identific |
|
| July 10, 2020 |
XNCR / Xencor, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Xencor Inc. Title of Class of Securities: Common Stock CUSIP Number: 98401F105 Date of Event Which Requires Filing of this Statement: June 30, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1( |
|
| June 26, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2020 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State of incorporation) (Commission File No.) (IRS Employer Identifica |
|
| June 17, 2020 |
XNCR / Xencor, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Xencor, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 98401F105 (CUSIP Number) June 8, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| June 10, 2020 |
XNCR / Xencor, Inc. / STAFFORD JOHN S III - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No. |
|
| June 5, 2020 |
XNCR / Xencor, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| June 3, 2020 |
XNCR / Xencor, Inc. / STAFFORD JOHN S III - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No. |
|
| May 20, 2020 |
XNCR / Xencor, Inc. / STAFFORD JOHN S III - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No. |
|
| May 12, 2020 |
XNCR / Xencor, Inc. / STAFFORD JOHN S III - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No. |
|
| May 8, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36182 Xencor, Inc. |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State of incorporation) (Commission File No.) (IRS Employer Identificati |
|
| May 7, 2020 |
Exhibit 99.1 Xencor Reports First Quarter 2020 Financial Results - Management to Host Conference Call at 4:30 p.m. ET Today - MONROVIA, Calif., May 7, 2020 - Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 202 |
|
| May 1, 2020 |
XNCR / Xencor, Inc. / STAFFORD JOHN S III - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No. |
|
| April 29, 2020 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 29, 2020 |
Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 8, 2020 |
XNCR / Xencor, Inc. / STAFFORD JOHN S III - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A (Amendment No. |
|
| February 25, 2020 |
Exhibit 4.3 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Xencor, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable prov |
|
| February 25, 2020 |
Exhibit 10.34 November 12, 2019 Dr. Allan S. Yang Dear Dr. Yang, Congratulations! I am pleased to confirm our offer of a position as Senior Vice President and Chief Medical Officer reporting to the President & CEO. The specifics of this offer, subject to approval by the Board of Directors, are as follows: · Annual base salary of Four Hundred Sixty Five Thousand dollars ($465,000), less standard wi |
|
| February 25, 2020 |
February 25, 2020 (File No. 333-236607) As filed with the Securities and Exchange Commission on February 24, 2020 Registration No. |
|
| February 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36182 Xencor, Inc. |
|
| February 25, 2020 |
Exhibit 10.33 revised August 5, 2019 Ms. Celia Eckert Dear Ms. Eckert, Congratulations! I am pleased to confirm our offer of a position as Vice President, General Counsel and Corporate Secretary reporting to the President & CEO. The specifics of this offer, subject to approval by the Board of Directors, are as follows: · Start date of September 3rd, 2019 · Annual base salary of Three Hundred Seven |
|
| February 24, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2020 XENCOR, INC. (Exact name of registrant as specified in its charter) Delaware 001-36182 20-1622502 (State of incorporation) (Commission File No.) (IRS Employer Identi |
|
| February 24, 2020 |
Exhibit 99.1 Xencor Reports Fourth Quarter and Full Year 2019 Financial Results - Management to Host Conference Call at 4:30 p.m. ET Today - MONROVIA, Calif., Feb. 24, 2020 - Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter a |
|
| February 14, 2020 |
45782T105 / Inmune Bio Inc. / Xencor Inc - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
XNCR / Xencor, Inc. / Redmile Group, LLC - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Xencor, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 98401F105 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 12, 2020 |
XNCR / Xencor, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
